To join this case, fill out the form below
Akero Therapeutics, Inc. Investigation
By clicking on the Submit button below, I acknowledge that I have read the Retainer Agreement and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
By clicking on the Submit button below, I acknowledge that I have read the Derivative Retention Letter and agree to retain WeissLaw LLP to file an action against the Company in connection with this matter. WeissLaw LLP will prosecute the action on a contingent fee basis and will advance all costs and expenses.
A signed Retainer Agreement will be sent to your email shortly.
Oops! Something went wrong while submitting the form.

Akero Therapeutics, Inc. Investigation

We are investigating possible breaches of fiduciary duty and violations of the federal securities laws by the Board of Directors and senior officers of Akero Therapeutics, Inc.  (NASDAQ: AKRO) (“Akero” or the “Company”), concerning the Company’s development of efruxifermin to treat nonalcoholic steatohepatitis (NASH) patients with severe liver disease.

According to numerous news sources, the Company’s drug performance fell short of its primary end point versus the placebo group in a phase 2b midstage study finding mixed statistically significant improvement after 36 weeks in patients receiving efruxifermin for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis, or NASH. On this news, the Company’s stock price dropped from $48.54 on October 9 to close at $18.15 per share on October 10, 2023, a 60% decline. Analysts have correspondingly significantly reduced their stock price targets for the Company.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients.  For more information about the firm, please go to: http://www.weisslaw.co

Other Cases

April 5, 2024

Shockwave Medical, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Shockwave Medical, Inc. (“Shockwave” or the “Company”) (NASDAQ: SWAV), in connection with its acquisition by Johnson & Johnson (NYSE: JNJ). Under the merger agreement, the Company’s shareholders will receive $335.00 per share. The transaction is valued at approximately $13.1 billion.

Join Case →

April 4, 2024

ChampionX Corporation Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) in connection with its acquisition by Schlumberger Limited (“Schlumberger”)(NYSE: SLB). Under the terms of the merger agreement, the Company’s shareholders will receive 0.735 shares of Schlumberger common stock for each share of ChampionX common stock owned, representing implied per-share consideration of $40.32 based upon Schlumberger’s April 3, 2024 closing price of $54.86.

Join Case →

April 4, 2024

Endeavor Group Holdings, Inc. Investigation

We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Endeavor Group Holdings, Inc. (“Endeavor Group” or the “Company”) (NYSE: EDR), in connection with its acquisition by Silver Lake. Under the merger agreement, the Company’s shareholders will receive $27.50 per share.

Join Case →

Where to find us?

new york

305 Broadway, 7th FI
New York, NY 10007
(212) 682-3025

california

8383 Wilshire Blvd., Suite 935
Beverly Hills, CA 90211
(310) 208-2800

georgia

476 Hardendorf Ave. NE
Atlanta, GA 30307
(404) 692-7910

NEW JERSEY

4 Brighton Rd, Suite. 204
Clifton, NJ 07012

Copyright 2022 Weiss Law. All rights reserved

Attorney AdvertisingLegal

Design by Cramdyn